What Are the Options If Biologics Don’t Work for Crohn’s?

When a biologic medication stops controlling Crohn’s disease, or never worked in the first place, the path forward is not a dead end. Options range from optimizing the biologic you’re already on, to switching drug classes, to newer oral medications, combination therapies, surgery, and dietary interventions. The specific strategy depends on why the biologic failed, which makes understanding that failure the first step toward finding something that works.

Why Biologics Fail in the First Place

Biologic failure falls into two broad categories, and they lead to different next steps. Primary non-response means the drug never worked from the start. Secondary loss of response means it worked for a while and then stopped. The distinction matters because primary non-responders to anti-TNF drugs tend to do worse on a second biologic overall, suggesting the underlying disease biology may not be driven by the pathway that drug targets.¹

For people who lose response over time, the most common culprit is immunogenicity. Your immune system can produce antibodies against the biologic drug itself, which drag down the drug’s concentration in your blood and block its activity.² This is a well-documented cause of treatment failure across different biologics used in inflammatory bowel disease.³ When anti-drug antibodies are the problem, the fix is sometimes straightforward. When the drug itself is simply the wrong tool for your disease, you need a different approach entirely.

Getting More From Your Current Biologic

Before abandoning a biologic altogether, doctors often try to optimize it. If blood tests show that your drug levels are low, increasing the dose or shortening the interval between infusions or injections can recapture a response. This approach makes the most sense when the biologic initially worked and you’re dealing with secondary loss of response driven by low drug levels rather than a fundamental mismatch between the drug and your disease.

For infliximab, one of the most commonly used anti-TNF drugs, dose escalation recaptured an early response in roughly three-quarters of patients, and about half maintained that response at 12 months.⁴ Those numbers are decent but not overwhelming, and they mean dose escalation buys time for some people rather than solving the problem permanently.

Ustekinumab, which targets a different immune pathway, shows a similar pattern. A meta-analysis found that about 55% of patients who had lost response or responded inadequately achieved a clinical response after dose escalation, and shortening the time between injections alone recaptured response in a similar proportion. Roughly 29% reached endoscopic remission, meaning the intestinal lining actually healed as confirmed by scope.⁵ A separate study confirmed that shortening the ustekinumab dosing interval brought down markers of inflammation and pushed some patients into clinical remission, though the responses were partial for many.⁶

The takeaway is practical: if your biologic is fading, dose optimization is worth trying before you switch, but you and your gastroenterologist should have a clear timeline. If a dose bump doesn’t improve things within a few months, it’s time to move on.

Switching to a Different Biologic Class

If you’ve been on an anti-TNF drug and it’s failed, the next question is whether to try a second anti-TNF or switch to a biologic that works through a different mechanism entirely. The evidence leans toward switching classes. In a large real-world study, patients who switched from an anti-TNF to a biologic with a different mechanism stayed on their new drug longer than patients who cycled to a second anti-TNF. Persistence on the new therapy was about 44% higher in the switching group at 12 months.⁷

Vedolizumab, which targets gut-specific immune cell trafficking, and ustekinumab, which blocks interleukin-12 and interleukin-23, are both options after anti-TNF failure. They tend to be somewhat less effective in people who’ve already failed an anti-TNF compared to biologic-naive patients, but a meaningful number of patients still respond.⁸

IL-23 Inhibitors

The newest biologic class making a real difference for Crohn’s patients is the selective IL-23 inhibitors, with risankizumab leading the way. In two large phase 3 trials, risankizumab produced clinical remission in roughly 42-45% of patients at 12 weeks, compared to about 20-25% with placebo. Endoscopic response rates were also substantially higher, landing between 29-40% versus about 11-12% on placebo.⁹

What’s especially encouraging is that risankizumab performs well even in people who’ve already been through multiple biologics. A systematic review confirmed high clinical remission rates and endoscopic healing in biologic-refractory patients.¹⁰ Real-world data from biologic-experienced patients showed that about 31% achieved steroid-free clinical remission by week 12, with the numbers climbing to 48% among patients who continued to week 24. The drug’s effectiveness was comparable regardless of whether patients had previously been exposed to ustekinumab, anti-TNF agents, or vedolizumab.¹¹

JAK Inhibitors

Unlike biologics, which are large proteins delivered by injection or infusion, JAK inhibitors are small molecules taken as pills. Upadacitinib is the first JAK inhibitor approved for Crohn’s disease, and the trial results were strong. In two induction studies, upadacitinib at 45 mg produced clinical remission in about 39-50% of patients versus 21-29% on placebo, and endoscopic response in roughly 35-46% versus 4-13% on placebo. In the maintenance study, the 30 mg dose maintained clinical remission in about 48% of patients at one year versus 15% on placebo.¹²

Real-world results from patients who had already failed biologics tell a similar story, with about 43% achieving clinical remission during induction.¹³ Other JAK inhibitors in the same family have shown promise too. Filgotinib, in a phase 2 trial, pushed 47% of patients into clinical remission compared to 23% on placebo, with an even larger gap in patients who had never been on an anti-TNF.¹⁴

JAK inhibitors do come with safety considerations that differ from biologics. A meta-analysis of randomized trials found that while the overall rate of serious side effects did not significantly differ from placebo, upadacitinib was associated with higher rates of low white blood cell counts and elevated creatine kinase levels. On the positive side, it was actually associated with lower rates of anemia and joint pain compared to placebo.¹⁵ Systematic reviews have also flagged dose-dependent risks of infections including shingles, and the need for regular monitoring of blood counts and lipid levels.¹⁶ These are manageable risks for most people, but they do make ongoing lab work more important than with some biologics.

Dual Targeted Therapy

For patients who have exhausted standard single-agent options, some specialists are now combining two biologic or targeted therapies simultaneously. This is still considered an off-label strategy and not routinely used, but the early data from refractory patients is hard to ignore.

In one retrospective study of refractory Crohn’s patients on dual therapy, 70% had a clinical response and 60% achieved clinical remission. Endoscopic response occurred in 60%, and 45% reached endoscopic remission. No major adverse events like serious infections or blood clots were recorded.¹⁷ A larger retrospective study, mostly pairing a biologic with a JAK inhibitor, found endoscopic improvement in 69% of matched samples and clinical improvement reported by about 73% of patients, with significant drops in inflammatory markers. Adverse events were mostly upper respiratory infections and skin issues, with no blood clots.¹⁸

An earlier study of patients on two biologics simultaneously showed more modest results, with about half achieving clinical response and 41% reaching clinical remission, but still demonstrated meaningful reductions in endoscopic disease activity and inflammatory markers. The rate of adverse events was about 13%.¹⁹ Dual targeted therapy is still in its early innings. These are all observational studies with small numbers, and the ideal drug combinations and patient selection criteria remain unclear. But for people who have truly run out of individual options, this approach is gaining traction at academic centers.

Surgery as a Strategic Option

Surgery for Crohn’s tends to carry an undeserved reputation as the last resort, something you turn to only when everything else has failed. The reality is more nuanced. For localized disease, particularly in the ileocecal region where the small intestine meets the colon, surgical resection can be highly effective and has been shown to be a reasonable alternative to biologics in terms of quality of life and cost.²⁰

Timing matters. Research shows that delaying surgery increases the risk of major complications. Each additional year between diagnosis and surgery was independently associated with higher complication rates, and preoperative steroid use was an even stronger risk factor for serious problems including leaks at the surgical connection point.²¹ The implication is that if surgery is on the table, doing it sooner rather than later, and ideally while you’re off steroids, produces better outcomes.

For patients whose main problem is a narrowed section of bowel (a stricture) rather than active inflammation, endoscopic balloon dilation offers a less invasive alternative to surgery. It works best for short, accessible, fibrotic strictures and can preserve intestinal length, which matters when Crohn’s has already required previous resections.²² Long-term follow-up suggests that balloon dilation is a good first-line therapy for suitable strictures, though if the intervals between dilations keep getting shorter, it’s a signal that surgery should be discussed.²³

Dietary Approaches

Diet is not a replacement for medical therapy in moderate to severe Crohn’s, but specific dietary interventions have shown real results, particularly as add-on or bridge strategies. Exclusive enteral nutrition, which replaces all food with a liquid formula diet, is well established in pediatric Crohn’s and is gaining ground in adults. A study of adults with complicated Crohn’s (including fistulas, abscesses, and strictures) treated with exclusive enteral nutrition found that about 80% achieved full clinical remission, with significant improvements in fistula closure and abscess resolution.²⁴

The Crohn’s Disease Exclusion Diet is a newer food-based approach that restricts specific components thought to promote intestinal inflammation while allowing whole foods. In a pilot trial of adults with mild-to-moderate Crohn’s, about 57-68% achieved clinical remission by week 6, and 80% of those who achieved remission maintained it through week 24. About a third showed endoscopic remission at 24 weeks, and no serious adverse events were reported.²⁵ Real-world application of this diet in an Australian adult population has confirmed its feasibility as a food-based therapy for inducing remission.²⁶

These dietary interventions are most useful as induction strategies or as tools to bridge the gap between medications. They require significant commitment and ideally dietitian guidance, but they carry virtually no safety concerns, which makes them attractive for patients wary of adding more drugs.

What’s Coming Down the Pipeline

The most exciting area of development for refractory Crohn’s is the anti-TL1A class. TL1A is a signaling molecule that drives both inflammation and the fibrosis (scarring) that causes strictures, meaning drugs that block it could potentially address two of Crohn’s biggest problems at once. Phase 2 trials have shown promising improvements in endoscopic and histologic outcomes for both Crohn’s and ulcerative colitis.²⁷ In a phase 2a study specifically in Crohn’s patients, many of whom had already failed other therapies, the anti-TL1A antibody tulisokibart achieved endoscopic response in 26% of participants at week 12, with most adverse events being mild to moderate.²⁸ Multiple anti-TL1A drugs are now in phase 3 trials, and this class could become a standard option within a few years.

Fecal microbiota transplantation remains investigational for Crohn’s but has generated intriguing results. In a study of 30 patients with refractory disease, FMT achieved clinical improvement in about 87% and clinical remission in about 77% at one month, though these rates decreased over time without repeated treatments.²⁹ Case reports have also documented individual patients achieving clinical remission and endoscopic improvement after biologic failure.³⁰ FMT is not yet an approved therapy for Crohn’s, and there are unresolved questions about donor selection, delivery method, and how many treatments are needed, but it represents a fundamentally different approach to the disease.

Autologous stem cell transplantation, where your own blood-forming stem cells are harvested and then reinfused after intense chemotherapy wipes out the existing immune system, has been tried in severe refractory cases. A European survey found that 68% of patients experienced complete remission or significant improvement, and over a quarter needed no further medical therapy at all after the procedure. Remarkably, 57% of patients who restarted medications responded to drugs they had previously failed.³¹ However, a randomized trial using a reduced-intensity regimen, while showing decreased endoscopic disease activity, concluded that the significant adverse events made that particular protocol unsuitable for clinical use.³² Stem cell transplant for Crohn’s remains reserved for the most severe, otherwise-untreatable cases and is available only at specialized centers.

The Biomarker Problem

One reason so many Crohn’s patients cycle through medications is that doctors currently lack reliable ways to predict which drug will work for which patient before starting treatment. Researchers are working on this through what’s broadly called precision medicine. A systematic review of biomarker studies found that approaches using genomics, gene expression profiling, protein markers, gut microbiome analysis, and metabolic signatures can all predict treatment response to some degree. Models that combine multiple types of data tend to perform better than any single marker alone.³³ None of these tools are ready for routine clinical use yet, but they represent the long-term solution to the trial-and-error cycle that defines Crohn’s treatment today.

Insurance Barriers That Affect Your Options

Even when a clear next treatment exists, getting access to it can be its own battle. Insurance step therapy mandates, which require you to try and fail a cheaper drug before your insurer will cover the one your doctor prescribed, are a widespread problem. A large survey by the Crohn’s & Colitis Foundation found that about 25% of patients who were prescribed IBD medications in the prior year experienced step therapy mandates. Of those, 85% reported adverse health outcomes from being unable to get or delayed in getting their prescribed treatment.³⁴

Delays in biologic approval directly worsen outcomes. Patients with active disease who experienced delays in biologic initiation had roughly 80% more days between the initial denial and eventual approval, meaning the sickest patients waited the longest.³⁵ If you’re facing a denial, working with your gastroenterologist’s office on a peer-to-peer review or appeal is often worth the effort. Patient advocacy organizations like the Crohn’s & Colitis Foundation also offer resources for navigating insurance challenges. The treatment options exist. Sometimes the harder part is making sure you can actually get them.

Symptom Relief While You Search for the Right Therapy

While you and your doctor work through the options above, managing day-to-day symptoms matters. Cannabis-based products have shown short-term improvements in quality of life for patients with refractory Crohn’s symptoms, though the evidence is limited to symptom relief rather than any proven anti-inflammatory effect.³⁶ It remains unclear whether cannabinoids reduce intestinal inflammation or simply mask symptoms like pain and poor appetite, which is an important distinction since controlling inflammation is what prevents long-term damage.³⁷ Gut-directed psychological therapies like hypnotherapy have also been explored as adjunctive treatments and may help with the significant quality-of-life burden that accompanies refractory disease, though the evidence base is still early.

None of these complementary approaches should replace the search for effective disease-modifying treatment. But they can make the journey more bearable, and for patients cycling through medications over months or years, that matters.